HK1198145A1 - Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)-phenol and pregabalin or gabapentin 3-(3--1--2--)- - Google Patents

Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)-phenol and pregabalin or gabapentin 3-(3--1--2--)-

Info

Publication number
HK1198145A1
HK1198145A1 HK14111224.9A HK14111224A HK1198145A1 HK 1198145 A1 HK1198145 A1 HK 1198145A1 HK 14111224 A HK14111224 A HK 14111224A HK 1198145 A1 HK1198145 A1 HK 1198145A1
Authority
HK
Hong Kong
Prior art keywords
pregabalin
gabapentin
dimethylamino
phenol
propyl
Prior art date
Application number
HK14111224.9A
Other languages
English (en)
Chinese (zh)
Inventor
Klaus Schiene
Petra Bloms-Funke
Thomas Christoph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1198145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1198145A1 publication Critical patent/HK1198145A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK14111224.9A 2008-09-05 2011-12-13 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)-phenol and pregabalin or gabapentin 3-(3--1--2--)- HK1198145A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
HK1198145A1 true HK1198145A1 (en) 2015-03-13

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14111224.9A HK1198145A1 (en) 2008-09-05 2011-12-13 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)-phenol and pregabalin or gabapentin 3-(3--1--2--)-
HK11113438.0A HK1159011A1 (en) 2008-09-05 2011-12-13 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)- phenol and an antiepileptic 3-(3--1--2--)-

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11113438.0A HK1159011A1 (en) 2008-09-05 2011-12-13 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)- phenol and an antiepileptic 3-(3--1--2--)-

Country Status (29)

Country Link
US (1) US20100063148A1 (es)
EP (2) EP2331210B1 (es)
JP (4) JP5731387B2 (es)
KR (3) KR101641519B1 (es)
CN (2) CN102159284B (es)
AR (2) AR073361A1 (es)
AU (3) AU2009289776A1 (es)
BR (1) BRPI0920521A2 (es)
CA (1) CA2735857C (es)
CL (1) CL2011000317A1 (es)
CO (1) CO6382142A2 (es)
CY (2) CY1115751T1 (es)
DK (2) DK2331210T3 (es)
EC (1) ECSP11010869A (es)
ES (2) ES2719900T3 (es)
HK (2) HK1198145A1 (es)
HR (2) HRP20140663T1 (es)
HU (1) HUE043278T2 (es)
IL (3) IL211135A (es)
LT (1) LT2735338T (es)
MX (1) MX2011002339A (es)
PE (5) PE20142372A1 (es)
PL (2) PL2331210T3 (es)
PT (2) PT2735338T (es)
RU (2) RU2571501C2 (es)
SI (2) SI2331210T1 (es)
TR (1) TR201904388T4 (es)
WO (1) WO2010025931A2 (es)
ZA (1) ZA201101449B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
PE20142372A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
PT2582366E (pt) 2010-06-15 2016-01-26 Gruenenthal Gmbh Combinação terapêutica para o tratamento da dor
BR112013000190A2 (pt) 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
RS54711B1 (en) * 2011-03-04 2016-08-31 Grünenthal GmbH PARENTERAL TAPENTADOL ADMINISTRATION
EP2753302B1 (en) * 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
DK2736501T3 (en) * 2011-07-29 2018-02-26 Gruenenthal Gmbh Intrathecal or epidural administration of 3 - [(1S, 2S) -3- (DIMETHYLAMINO) -1-ETHYL-2-METHYLPROPYL] PHENOL
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
EP2914243A1 (en) * 2012-11-01 2015-09-09 Torrent Pharmaceuticals Limited Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3393655T3 (da) 2015-12-22 2021-03-15 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PT1210118E (pt) * 1999-08-20 2005-02-28 Ortho Mcneil Pharm Inc Composicao compreendendo um material tramadol e um farmaco anticonvulsivo
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1480639A1 (en) * 2002-02-22 2004-12-01 Warner-Lambert Company LLC Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
ES2358763T3 (es) * 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
CN104958282B (zh) * 2007-11-23 2018-05-29 格吕伦塔尔有限公司 他喷他多组合物
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
PE20142372A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Also Published As

Publication number Publication date
KR101641519B1 (ko) 2016-07-21
US20100063148A1 (en) 2010-03-11
PE20190914A1 (es) 2019-06-26
WO2010025931A3 (en) 2010-06-17
CY1121492T1 (el) 2020-05-29
AU2018202879B2 (en) 2020-03-12
WO2010025931A2 (en) 2010-03-11
KR101730924B1 (ko) 2017-04-27
HRP20190500T1 (hr) 2019-08-09
CA2735857C (en) 2019-05-28
IL237391A (en) 2017-12-31
EP2735338A1 (en) 2014-05-28
HUE043278T2 (hu) 2019-08-28
IL237391A0 (en) 2015-04-30
PE20110291A1 (es) 2011-06-04
PT2331210E (pt) 2014-08-25
SI2735338T1 (sl) 2019-04-30
AU2018202879A1 (en) 2018-05-17
EP2331210A2 (en) 2011-06-15
IL237392B (en) 2019-08-29
MX2011002339A (es) 2011-04-04
PE20142371A1 (es) 2015-02-04
RU2571501C2 (ru) 2015-12-20
ES2719900T3 (es) 2019-07-16
AU2016203053B2 (en) 2018-01-25
CN105520924A (zh) 2016-04-27
DK2735338T3 (en) 2019-04-23
ES2513394T3 (es) 2014-10-27
IL211135A (en) 2017-09-28
CL2011000317A1 (es) 2011-06-17
ECSP11010869A (es) 2011-04-29
RU2011112444A (ru) 2012-10-10
EP2331210B1 (en) 2014-07-09
JP2019131578A (ja) 2019-08-08
CA2735857A1 (en) 2010-03-11
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
PT2735338T (pt) 2019-05-24
PL2735338T3 (pl) 2019-07-31
AU2016203053A1 (en) 2016-06-02
SI2331210T1 (sl) 2014-10-30
DK2331210T3 (da) 2014-08-11
CN102159284B (zh) 2015-12-09
HRP20140663T1 (hr) 2014-10-10
AR117613A2 (es) 2021-08-18
CO6382142A2 (es) 2012-02-15
AU2009289776A1 (en) 2010-03-11
AR073361A1 (es) 2010-11-03
KR20170048602A (ko) 2017-05-08
IL237392A0 (en) 2015-04-30
EP2735338B1 (en) 2019-02-06
HK1159011A1 (en) 2012-07-27
RU2674150C1 (ru) 2018-12-05
JP2012501986A (ja) 2012-01-26
JP5731387B2 (ja) 2015-06-10
KR20110057144A (ko) 2011-05-31
BRPI0920521A2 (pt) 2018-01-16
CN105520924B (zh) 2019-04-09
PE20142372A1 (es) 2015-02-04
CN102159284A (zh) 2011-08-17
IL211135A0 (en) 2011-04-28
KR20160086981A (ko) 2016-07-20
TR201904388T4 (tr) 2019-05-21
PE20142357A1 (es) 2015-02-04
PL2331210T3 (pl) 2014-12-31
JP2015096530A (ja) 2015-05-21
ZA201101449B (en) 2011-10-26
CY1115751T1 (el) 2017-01-25
JP2017071636A (ja) 2017-04-13

Similar Documents

Publication Publication Date Title
HK1198145A1 (en) Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)-phenol and pregabalin or gabapentin 3-(3--1--2--)-
HUS000504I2 (hu) Relebaktám, adott esetben monohidrát formájában, és imipenem kombinációja
ZA201102762B (en) CO-CRYSTALS OF TRAMADOL AND NSAIDs
HK1205337A1 (en) Display and projector
EP2445340A4 (en) SUBSTITUTED HYDROXAMINE ACIDS AND USES THEREOF
BRPI0909750A2 (pt) dispositivo e cápsula para a preparação de uma bebida
IL210318A (en) Acetylation fatty acid salicylates and their uses
GB201013420D0 (en) Slowness-frequency projection display and animation
EP2519100A4 (en) INTERMEDIATE COMPOUNDS AND METHODS FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS
PL2474522T3 (pl) Agomelatyna i jej kompozycje farmaceutyczne
HK1152485A1 (en) A pharmaceutical composition comprising l-carnitine and dobesilate
ZA200905688B (en) Fungicidal mixtures of 1-Methylpyrazole-4-Ylcarboxylic acid anilides and azolopy-rimidinylamines
IL200514A0 (en) Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
EP2269612A4 (en) EYE DROP PREPARATION AND ITS USE
IL207508A0 (en) Dosage forms comprising gabapentin and a hydrophillic polymer and uses thereof
IL209698A (en) Use of Niportimox for the preparation of pharmaceuticals and preparations containing this Niportimox
PT2117519E (pt) Composição farmaceutica compreendendo tramadol e cetoprofeno
IL213128A0 (en) Processes for the preparation and purification of gabapentin enacarbil
EP2273993A4 (en) METHODS AND COMPOSITIONS FOR INTRACERATEDBROVENTRICULAR FELBAMATE ADMINISTRATION
GB0819293D0 (en) Radiofluorination
IL206555A0 (en) Matrix decoder
HU0800091D0 (en) Novel polymorphs and amorph forms of desvenlafaxine fumarate
HUP0900062A2 (en) Novel polymorphs and amorph forms of desvenlafaxine fumarate

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230901